title: In vivo protein synthetic rates of atrial, ventricular, and pulmonary tissue proteins in aortic constriction, goldblatt, and bromoethylamine models of hypertension.
abstract: Changes in tissue protein synthesis in hypertension have usually been measured in vitro in heart from acutely hypertensive rats without consideration of changes in atrial or pulmonary tissue or changes occurring in long-standing hypertension. The objective of the study was to investigate the in vivo changes in cardiopulmonary protein synthesis in three different rat models of chronic hypertension. Hypertension in aortic constriction, the Goldblatt model, and the bromoethylamine model were induced in rats for 30 days. At the end of the experimental period, in vivo rates of protein synthesis were measured with a flooding dose of [3H]phenylalanine (a method which effectively considers precursor pools). Concomitant measurements included quantification of contractile protein and RNA and DNA contents. Indices of protein breakdown were also assessed by selective measurement of protease activities. At the end of 30 days, aortic constriction induced marked increases in protein contents of the left ventricle, septum, left atria, and lungs. Accompanying changes included concomitant increases in RNA and DNA contents. Left ventricular myofibrillary, sarcoplasmic, and stromal protein contents increased in the aortic constriction model. Less marked changes occurred in the Goldblatt model, though the left atria were not significantly affected. In contrast, the bromoethylamine model had no effect on the protein or RNA contents of any region. In all cardiac regions of all three models, fractional rates of protein synthesis were not significantly affected. However, protein synthesis increased in the lungs of both the Goldblatt and bromoethylamine models at 30 days. Protease activities were decreased in the left ventricles of all three models at 30 days, with lysosomal protease activities declining in the aortic constriction model and cytoplasmic protease activities declining in the other two models. The failure of chronic hypertension to increase ventricular synthesis rates may represent inherent limitations in the time frame for measuring protein synthesis in vivo. However, at earlier time points (i.e., 10 days), the aortic constriction model was characterized by marked increases in left ventricular and atrial protein contents, RNA contents, and fractional rates of protein synthesis. This was consistent with the supposition that, in acute phases of hypertrophy, rates of protein synthesis increase, whereas in established hypertrophy, synthesis rates remain unchanged or decrease. The applicability of the aortic constriction model was investigated by examining the effects of the angiotensin converting enzyme inhibitor lisinopril (5 mg/kg/day). After 30 days treatment, lisinopril impeded the increase in left ventricular mixed and myofibrillar proteins. This effect was accompanied by an apparent increase in protein synthesis. In conclusion, although all three chronic models are able to induce hypertension, varying degrees of hypertrophy develop, which are more pronounced in the aortic constriction model. Accompanying changes include hypertrophy in the atria, reduced rates of ventricular proteolytic activity, and altered rates of protein metabolism in the lungs.
authors.affiliation: Department of Clinical Biochemistry, King's College Medical School, King's College, London, United Kingdom.
authors.forename: T
authors.initials: T
authors.lastname: Siddiq
authors.forename: V B
authors.initials: VB
authors.lastname: Patel
authors.forename: R
authors.initials: R
authors.lastname: Sherwood
authors.forename: P J
authors.initials: PJ
authors.lastname: Richardson
authors.forename: V R
authors.initials: VR
authors.lastname: Preedy
mesh_terms: D000818:Animals; D001012:Aorta, Abdominal / Q000473:pathology / Q000601:surgery; D001794:Blood Pressure / Q000187:drug effects; D003251:Constriction, Pathologic; D004247:DNA / Q000032:analysis; D004195:Disease Models, Animal; D010450:Endopeptidases / Q000096:biosynthesis; D005021:Ethylamines / Q000633:toxicity; D006325:Heart Atria / Q000378:metabolism* / Q000473:pathology; D006352:Heart Ventricles / Q000378:metabolism* / Q000473:pathology; D006978:Hypertension, Renovascular / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D017379:Hypertrophy, Left Ventricular / Q000378:metabolism / Q000473:pathology; D007679:Kidney Medulla / Q000187:drug effects / Q000473:pathology; D017706:Lisinopril / Q000627:therapeutic use; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D014176:Protein Biosynthesis; D012313:RNA / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar
chemical_list: D005021:Ethylamines; C004504:2-bromoethylamine; D012313:RNA; D004247:DNA; D017706:Lisinopril; D010450:Endopeptidases